BCL2 and neoplasm: Preclinical studies have shown that the Bcl-2/Bcl-xl dual target inhibitor ABT-737 significantly enhances the anti-tumor effects of chemotherapy and radiotherapy and is effective in a variety of hematological and solid tumors.